BICO - The Bio Convergence Company WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Support

BICO’s revenue and EBITDA for Q3, 2023 is expected to be above market expectations in light of general industry development. The EBITDA is expected to amount to SEK 64.2m (1.8), corresponding to a margin of 10.9 per cent (0.3). The EBITDA for the quarter deviates mainly due to effects from structured cost control and right sizing as well as seasonal volume effect resulting in higher operational efficiency. The adjusted EBITDA is expected to amount to SEK 69.2m (18.1), corresponding to a margin of 11.8 per cent (3.3). BICO expects the revenue for Q3 2023 to amount to SEK 587.2m (550.6) which corresponds to an increase of 6.6% per cent compared to the corresponding quarter previous year. The cash flow from operating activities is expected to amount to SEK 3.6m (-15.6). All amounts stated in this press release are preliminary and unaudited. BICO’s full financial performance will be presented in the interim report January – September 2023 released on November 14, 2023, at 07:00am CET, which means that the company is still in a quiet period. .